ProCE Banner Activity

My Thoughts on Key Studies in MDS From ASH 2021

Clinical Thought
In this commentary, Amy E. DeZern, MD, MHS, highlights the clinical implications of trials of novel treatment strategies for myelodysplastic syndromes reported at ASH 2021.

Released: February 16, 2022

Expiration: February 15, 2023

No longer available for credit.

Share

Faculty

Amy E. DeZern

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Gilead Sciences, Inc.

Novartis Pharmaceuticals Corporation

Taiho Oncology Inc

Faculty Disclosure

Primary Author

Amy E. DeZern, MD, MHS

Associate Professor
Oncology and Medicine
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Amy E. DeZern, MD, MHS, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Novartis, Taiho, and Takeda.

Additional Information

Program Medium

This program has been made available online.